{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/facial-flexural/genital-psoriasis/","result":{"pageContext":{"chapter":{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis","depth":2,"htmlHeader":"<!-- begin field 11a4eea5-e84d-4be0-83f9-48916ee5b338 --><h2>Scenario: Facial/flexural/genital psoriasis</h2><!-- end field 11a4eea5-e84d-4be0-83f9-48916ee5b338 -->","summary":"Covers the management of facial, flexural, and genital psoriasis in primary care.","htmlStringContent":"<!-- begin item 60654673-0473-4a9f-a1a4-8546d887ec9b --><!-- begin field d1ec5b5b-fee6-4bc3-8889-acbc015bb2bb --><p>From age 18 years onwards.</p><!-- end field d1ec5b5b-fee6-4bc3-8889-acbc015bb2bb --><!-- end item 60654673-0473-4a9f-a1a4-8546d887ec9b -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"79d65af8-8bf9-5f8b-983a-363d2f1fd4f3","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field db6efc92-1627-4b13-9a8c-b2ff891dde5d --><h3>How should I manage facial, flexural and genital psoriasis?</h3><!-- end field db6efc92-1627-4b13-9a8c-b2ff891dde5d -->","summary":null,"htmlStringContent":"<!-- begin item dee8a649-c38c-4056-b18b-d0dfffcee88e --><!-- begin field caa7a046-fbbd-44ac-81de-dbfcbb5ae718 --><p><strong>If the person has <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#facial-psoriasis\">facial</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#flexural-psoriasis\">flexural, or genital</a> psoriasis:</strong></p><ul><li>Offer advice on the nature of psoriasis, and explain that treatment is aimed at control of symptoms rather than cure, and that complete clearance of skin lesions may not be possible.</li><li>Reassure that it is not an infectious condition, and provide advice on sources of information and support, such as:<ul><li>The Psoriasis and Psoriatic Arthritis Alliance (PAPAA; website available at <a href=\"http://www.papaa.org/\" target=\"_blank\" data-hyperlink-id=\"a2ebbb7a-e694-4308-bd2c-a93100a4e377\">www.papaa.org</a>) is a national charity which provides information and advice on all aspects of psoriasis and psoriatic arthritis, including leaflets on <a href=\"http://www.papaa.org/sites/default/files/Psoriasis%20and%20sensitive%20areas%20final.pdf\" target=\"_blank\" data-hyperlink-id=\"915ad286-6929-4690-9e74-a93100a4e45c\">Psoriasis and sensitive areas</a> and <a href=\"http://www.papaa.org/sites/default/files/Genital_psoriasis_final_2017.pdf\" target=\"_blank\" data-hyperlink-id=\"050e819f-25d7-4230-a3d7-a93100a4e5eb\">Genital psoriasis</a>.</li><li>The Psoriasis Association (website available at <a href=\"https://www.psoriasis-association.org.uk/\" target=\"_blank\" data-hyperlink-id=\"e9ea9a20-4b5d-47de-b77c-a93100a4e5ef\">www.psoriasis-association.org.uk</a>) is a national charity and membership organization for people affected by psoriasis, which has a leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/SENSITIVE_2016.pdf\" target=\"_blank\" data-hyperlink-id=\"6cabb4c7-9a01-4c32-a41b-a93100a4e60c\">Psoriasis in sensitive areas</a>.</li></ul></li><li>Give general lifestyle advice to reduce the risk of exacerbations, such as advice on:<ul><li>Smoking cessation if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Drinking alcohol within recommended limits. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>Weight loss if the person is overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information. The PAPAA has an information leaflet on <a href=\"http://www.papaa.org/sites/default/files/Psoriatic_lifestyle_and_nutrition.pdf\" target=\"_blank\" data-hyperlink-id=\"3302cf43-d784-434c-ad50-a93100a4e61b\">Psoriatic lifestyle and nutrition</a>.</li></ul></li><li><ul></ul>Assess for associated stress, distress, anxiety and/or depression, and manage appropriately. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.<ul><li>The PAPAA has an information leaflet on <a href=\"http://www.papaa.org/sites/default/files/Psychological%20aspects%20of%20psoriasis%20final%20May%202015.pdf\" target=\"_blank\" data-hyperlink-id=\"f7b0f673-921b-4a8f-a628-a93100a4e62d\">Psychological aspects of psoriasis</a>.</li></ul></li><li>Offer treatment with <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/facial-flexural/genital-psoriasis/#topical-drug-treatment\">topical preparations</a>, depending on the person's preferences, cosmetic acceptability, practical aspects of application, and the site(s) and extent of psoriasis to be treated.<ul><li>The PAPAA has an information leaflet on <a href=\"http://www.papaa.org/sites/default/files/Treatments_Psoriasis_2017.pdf\" target=\"_blank\" data-hyperlink-id=\"e2185aad-f3ec-4bcb-8529-a93100a4e633\">Treatments for psoriasis: an overview</a>.</li><li>The British Association of Dermatologists has an information leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=123&itemtype=document\" target=\"_blank\" data-hyperlink-id=\"25d78240-a071-473a-98a4-a93100a4e63b\">Topical treatments for psoriasis</a>.</li><li>Advise that topical treatments may take several weeks to start to work, and if treatment is stopped suddenly, there may be a risk of relapse.<ul><li>Creams, lotions, or gels are suitable for widespread psoriasis.</li><li>Ointments are suitable for areas of skin with thick scale.</li><li>Lotions, solutions or gels are suitable for hair-bearing areas.</li></ul></li><li>Topical corticosteroids are only suitable for treating localized areas of psoriasis. Note: repeat prescriptions for topical corticosteroids should be carefully reviewed and supervised to identify any adverse effects, and to avoid use on widespread psoriasis where there is a risk of unstable disease.</li></ul></li><li>Arrange to review the person within four weeks after treatment has started and regularly thereafter, depending on clinical judgement, to:<ul><li>Assess the initial response to treatment, including the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a> of psoriasis.</li><li>Assess for any issues with topical application or adverse effects.</li><li>Reinforce the importance of adherence to treatments.</li></ul></li><li>Arrange to review the person at least annually if they are using multiple intermittent or short-term courses of potent topical corticosteroids to:<ul><li>Optimize treatment and assess for adverse effects such as skin atrophy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li><li>Assess disease <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a>, and assess for new joint symptoms that may suggest <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a>, and arrange specialist referral if appropriate.</li><li>Note: seek urgent specialist dermatology advice if there is any uncertainty about adverse effects or drug safety if the person is taking <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist drug treatments</a>.</li></ul></li><li>Assess the person's risk of cardiovascular disease at least every five years, especially if psoriasis is severe, depending on clinical judgement. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.<ul><li>The PAPAA has an information leaflet on <a href=\"http://www.papaa.org/sites/default/files/Ps%20and%20the%20heart%20final.pdf\" target=\"_blank\" data-hyperlink-id=\"cb576e6f-2bfd-4216-aa31-a93100a4e63b\">Psoriasis and the heart</a>.</li></ul></li><li>Advise the person on how to reduce the risk of venous thromboembolism, especially if psoriasis is severe. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/deep-vein-thrombosis/\">Deep vein thrombosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/dvt-prevention-for-travellers/\">DVT prevention for travellers</a> for more information.</li></ul><!-- end field caa7a046-fbbd-44ac-81de-dbfcbb5ae718 --><!-- end item dee8a649-c38c-4056-b18b-d0dfffcee88e -->","subChapters":[{"id":"b5985e6f-3427-5232-8b6f-6ee6cd19bd29","slug":"basis-for-recommendation-ebf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1e213027-1598-4e79-bfbf-7a2956d739ca --><h4>Basis for recommendation</h4><!-- end field 1e213027-1598-4e79-bfbf-7a2956d739ca -->","summary":null,"htmlStringContent":"<!-- begin item ebf13b56-b34f-4013-9090-3cffc03d12a8 --><!-- begin field 900e899f-9117-4e3b-870b-988910b4f678 --><p>The recommendations on management are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], a systematic review on weight loss intervention on disease severity of psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</p><h5>Giving lifestyle advice</h5><ul><li>The recommendation on lifestyle and weight loss advice is based on a systematic review of five randomized controlled trials (RCTs; number of participants not specified) which found strong evidence of a greater reduction in psoriasis severity scores in overweight or obese people receiving weight loss intervention (by diet or exercise) than a control group. The meta-analysis was limited, however, by the small number of included studies, the short follow-up period, and heterogeneity between studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>].</li></ul><h5>Arranging annual review</h5><ul><li>The recommendations on annual review are largely based on the SIGN clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li><li>The recommendation on seeking specialist dermatology advice if there is any uncertain about safety or appropriateness of specialist drug treatment is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Assessing cardiovascular disease risk</h5><ul><li>People with severe psoriasis are at increased cardiovascular risk, so these people should be screened using appropriate risk assessment tools to allow early management of modifiable risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</li></ul><!-- end field 900e899f-9117-4e3b-870b-988910b4f678 --><!-- end item ebf13b56-b34f-4013-9090-3cffc03d12a8 -->","subChapters":[]}]},{"id":"9cfee966-b2d8-5c14-ab91-e23b8827f626","slug":"topical-drug-treatment","fullItemName":"Topical drug treatment","depth":3,"htmlHeader":"<!-- begin field f5a54fd8-1bbf-404b-b95f-2f786b43c15c --><h3>What topical drug treatments should I offer?</h3><!-- end field f5a54fd8-1bbf-404b-b95f-2f786b43c15c -->","summary":null,"htmlStringContent":"<!-- begin item 01e831a2-f3fa-4d78-aac1-b2dbeadc4a81 --><!-- begin field 297c3266-aee8-45ed-8e7d-8c6c062b5cd7 --><ul><li><strong>Offer treatment with topical preparations, and consider whether <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/facial-flexural/genital-psoriasis/#referral\">referral</a> is needed if lesions are extensive, severe, or not responding to treatment. Options include:</strong><ul><li>An emollient to reduce scale and help relieve itch — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/emollients/\">Emollients</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information, <em>and</em><ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Moisturisers.pdf\" target=\"_blank\" data-hyperlink-id=\"179a2303-8419-48b2-981a-a93100ad14f5\">Moisturisers</a> or the Psoriasis and Psoriatic Arthritis Alliance leaflet on <a href=\"http://www.papaa.org/sites/default/files/emollients_June_2016.pdf\" target=\"_blank\" data-hyperlink-id=\"cf8fc033-344a-4523-baa1-a93100ad14f9\">Emollients and Psoriasis</a>.</li><li>Advise the person to avoid soap where possible if there is flexural or genital psoriasis, as soap is likely to irritate inflamed skin.</li></ul></li><li>A short-term mild- or moderately-potent topical corticosteroid preparation (applied once or twice daily) for up to two weeks. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.<ul><li>Advise on how to minimize the risk of corticosteroid adverse effects, such as stopping the topical corticosteroid once the skin is clear or nearly clear.</li><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Steroids.pdf\" target=\"_blank\" data-hyperlink-id=\"ef2fab57-a350-4d67-b77d-a93100ad1502\">Topical steroids</a>.</li><li>Note: do not prescribe potent- or very-potent topical corticosteroids to the face, flexures, or genital areas. Corticosteroid application to these areas may cause skin irritation, and there is a greater risk of adverse effects, such as skin atrophy, compared with use in other areas of the body.</li></ul></li></ul></li><li><strong>Review the person after four weeks.</strong><ul><li>If there is a good initial response, advise that repeated short courses of topical corticosteroids may be used to maintain disease control, however:<ul><li>A 'treatment break' of four weeks between corticosteroid courses is required.</li><li>Topical corticosteroids should only be used for 1–2 weeks each month.</li></ul></li><li>If there is a poor initial response, check adherence to treatment, and ask about any issues with application, cosmetic acceptability, or tolerability of topical treatments.</li></ul></li><li><strong>If there is ongoing treatment failure:</strong><ul><li>Consider whether there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a>, and manage appropriately.</li><li>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/facial-flexural/genital-psoriasis/#referral\">referral</a> to a dermatologist for specialist assessment and management.</li></ul></li></ul><!-- end field 297c3266-aee8-45ed-8e7d-8c6c062b5cd7 --><!-- end item 01e831a2-f3fa-4d78-aac1-b2dbeadc4a81 -->","subChapters":[{"id":"1da24a11-619a-5ca2-8c22-3d5161f8f869","slug":"basis-for-recommendation-6ab","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a360649b-a877-4e2c-b5ec-ceadc1faec24 --><h4>Basis for recommendation</h4><!-- end field a360649b-a877-4e2c-b5ec-ceadc1faec24 -->","summary":null,"htmlStringContent":"<!-- begin item 6ab793a2-4ecf-4fbb-ac6a-edef6f032310 --><!-- begin field 5fb850e4-3d59-4dce-9af8-125ba18257db --><p>The recommendations on topical drug treatments are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</p><h5>Choice of topical preparations</h5><ul><li>The recommendations on the use of emollients are based on the fact that they improve the skin's barrier function, reduce scale, and may increase the penetration and effectiveness of some active topical treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li><li>The recommendations on the use of mild- to moderate-potency topical corticosteroids are largely based on the clinical experience and expert opinion of the NICE guideline development group, as there were no specific trials that assessed the efficacy of topical corticosteroids for facial, flexural, or genital psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>]. This is consistent with expert opinion in the SIGN clinical guideline, which recommends moderate-potency topical corticosteroids first-line for short-term use in facial and flexural psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li><li>The SIGN guideline cites very limited evidence for the intermittent use of topical vitamin D preparations if moderate-potency corticosteroids have not resulted in symptom improvement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], however NICE found a lack of trial data to support this and does not recommend this management approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li><li>The NICE guideline found no published trial evidence that coal tar or dithranol are effective for the treatment of facial, flexural, or genital psoriasis, so these treatments are not recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li></ul><h5>Advising on corticosteroid 'treatment breaks'</h5><ul><li>The recommendation on corticosteroid 'treatment breaks' is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>] and on expert opinion in a review article on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>].<ul><li>The NICE guideline states that continuous use of topical corticosteroids can cause adverse effects such as irreversible skin atrophy, striae, and telangiectasia, and may cause psoriasis to become unstable, if applied to extensive areas.</li><li>In addition, the risk of corticosteroid adverse effects may be increased in flexural areas due to the occlusive effect of skin folds.</li><li>The review article highlights that long-term corticosteroid use may lead to potential tachyphylaxis, where efficacy decreases over time, as well as adverse effects such as skin atrophy.</li></ul></li></ul><!-- end field 5fb850e4-3d59-4dce-9af8-125ba18257db --><!-- end item 6ab793a2-4ecf-4fbb-ac6a-edef6f032310 -->","subChapters":[]}]},{"id":"26d1da0c-3aa3-5933-a7bc-a379c02aae46","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 5ac32718-1bef-4f2d-aef0-247d21428a5d --><h3>When should I refer a person with facial, flexural, or genital psoriasis?</h3><!-- end field 5ac32718-1bef-4f2d-aef0-247d21428a5d -->","summary":null,"htmlStringContent":"<!-- begin item 503e9188-6d77-4708-aaa0-c3c13aca39fb --><!-- begin field fac61252-dd33-48ec-9028-87aeead493fe --><ul><li>If the person presents with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a>, this should be managed as a medical emergency:<ul><li>Arrange for urgent same-day specialist dermatology assessment and ongoing management.</li></ul></li><li>Arrange referral to a dermatologist for <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement, if:<ul><li>There is uncertainty about the diagnosis.</li><li>Psoriasis is extensive, for example more than 10% of the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">body surface area</a> is affected.</li><li>Psoriasis is at least moderately severe, as measured by the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">Physician&#39;s Global Assessment</a> tool.</li><li>Psoriasis is resistant to <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/facial-flexural/genital-psoriasis/#topical-drug-treatment\">topical drug treatments</a> in primary care, or treatments are not tolerated.</li><li>Continuous treatment with topical corticosteroids is needed to maintain control of psoriasis <em>and </em>there is a significant risk of adverse effects.</li><li>There is a significant impact on the person's physical, psychological, or social wellbeing.</li><li>Additional information or education is needed (for example about application of topical treatments).</li></ul></li><li>Arrange an urgent referral to a rheumatologist if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> is suspected.</li></ul><!-- end field fac61252-dd33-48ec-9028-87aeead493fe --><!-- end item 503e9188-6d77-4708-aaa0-c3c13aca39fb -->","subChapters":[{"id":"a97da13d-d84c-5dae-9f0e-d78de43a9e67","slug":"basis-for-recommendation-1ad","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 65e5fdd6-15a0-4c46-8d03-20010b281653 --><h4>Basis for recommendation</h4><!-- end field 65e5fdd6-15a0-4c46-8d03-20010b281653 -->","summary":null,"htmlStringContent":"<!-- begin item 1ad0367f-42b1-45aa-8ff3-ee4e7cead238 --><!-- begin field 20b77f38-67ec-4619-aa0d-d9c43156c7e8 --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], and a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</p><ul><li>Topical calcineurin inhibitors such as tacrolimus and pimecrolimus may be a specialist option if facial or flexural psoriasis does not respond to optimal primary care management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li><li>The recommendation on arranging urgent referral to rheumatology if psoriatic arthritis is suspected is based on the fact that an early diagnosis should be made to reduce the risk of erosive and progressive joint damage and loss of function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</li></ul><!-- end field 20b77f38-67ec-4619-aa0d-d9c43156c7e8 --><!-- end item 1ad0367f-42b1-45aa-8ff3-ee4e7cead238 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}